Key Stats for HIMS Stock
- Past week’s performance: +6.6%
- 52-week range: $14 to $70
- Valuation model target price: $34
- Implied upside: 43.6% over 2.6 years
Value your favorite stocks like HIMS with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Hims & Hers Health (HIMS) reported first-quarter 2026 revenue of $608 million, slightly below the analyst consensus estimate of $617 million. Despite that modest miss, the stock gained 6.6% over the week. Investor attention quickly shifted to the company’s strategic expansion moves rather than the short-term earnings gap. The growth story remained constructive even as quarterly results came in just under expectations.
The most significant development was the launch of generic semaglutide access in Canada on May 21, 2026. Semaglutide is the active ingredient in GLP-1 weight loss drugs like Ozempic and Wegovy, which help patients manage obesity by regulating appetite.
Hims partnered with Canadian generic manufacturer Apotex to offer the product starting at CAD 149 per month, following Novo Nordisk’s patent expiry in Canada. This international expansion represents the company’s first major move beyond the US telehealth market.
Hims also priced an upsized $350 million convertible senior notes offering in May 2026. The company originally announced a $300 million deal, but increased the size after strong investor demand emerged. Management stated that proceeds would fund international expansion and accelerate AI investment across the telehealth platform.
The convertible notes mature in 2032, giving Hims a long runway to deploy capital toward its strategic priorities without near-term dilution pressure. Going forward, HIMS stock will largely track regulatory clarity around GLP-1 products and the pace of revenue growth from international markets.
See analysts’ growth forecasts and price targets for HIMS (It’s free) >>>
Is HIMS Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): 20%
- Operating Margins: 4.5%
- Exit P/E Multiple: 23x
Based on these inputs, the model estimates a target price of $34, implying 43.6% total upside from the current share price of $24 and an annualized return of 14.9% over the next 2.6 years.
Hims & Hers is a telehealth platform delivering prescription medications and wellness products directly to consumers across weight loss, sexual health, dermatology, and mental health categories.
The 20.0% revenue CAGR assumption reflects a meaningful deceleration from historically explosive growth, including 59% growth over the past year. That deceleration is reasonable as the company scales from a larger base and navigates regulatory headwinds around compounded GLP-1 medications in the US market.
The 4.5% operating margin target is conservative for a platform carrying a gross margin above 72%. But it reflects continued heavy investment in customer acquisition, technology, and international market entry.
If Hims can grow average revenue per customer while disciplining its marketing spend, operating margins could expand well ahead of the model’s conservative assumptions, creating upside beyond the $34 target price.
At 23.0x exit earnings and a 14.9% projected annual return, the model places HIMS in a compelling position. The stock trades more than 66% below its 52-week high of $70, so the current price embeds a substantial discount that accounts for both regulatory uncertainty and the recent earnings miss.
For investors comfortable with those risks, 14.9% projected annually is meaningfully above the threshold that signals an attractive long-term opportunity.
What’s Driving HIMS Stock Going Forward?
The regulatory environment remains the most critical swing factor for HIMS. The Department of Health and Human Services referred Hims to the Department of Justice in February 2026 over potential violations related to compounded semaglutide advertising.
Hims has since shifted its GLP-1 strategy toward offering FDA-approved branded and generic products rather than compounded alternatives. This pivot reduces legal and regulatory exposure while aligning product offerings with the most defensible part of the market.
International expansion is the most exciting near-term growth catalyst. The Canadian semaglutide launch through Apotex is the first step in a broader global buildout, supported by the $1.15 billion acquisition of Australian telehealth platform Eucalyptus completed in early 2026.
Eucalyptus brings established market presence and operational infrastructure across several international markets, giving Hims a faster path to international scale than building from scratch would allow.
Artificial intelligence investment is increasingly central to the company’s platform roadmap. The $350 million capital raise was explicitly earmarked for AI-driven platform development alongside international expansion.
If HIMS can use AI to improve clinical decision-making, personalize treatment protocols, and reduce customer service costs, the operating leverage from those improvements could be significant and ahead of model forecasts.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Hims & Hers Health, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up HIMS, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track HIMS alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze HIMS stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
